| Hazard Information | Back Directory | [Uses]
Tilsotolimod is a synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. | [References]
[1] Karime C, Wang J, Woodhead G, et al. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma.?Expert Opin Investig Drugs. 2022;31(1):1-13. DOI:10.1080/13543784.2022.2019706
[2] Haymaker C, Johnson DH, Murthy R, et al. Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.?Cancer Discov. 2021;11(8):1996-2013. DOI:10.1158/2159-8290.CD-20-1546
[3] Babiker H, Borazanci E, Subbiah V, et al. Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).?Clin Cancer Res. 2022;28(23):5079-5087. DOI:10.1158/1078-0432.CCR-21-4486 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|